Michele Korfin
Director/Board Member at ORGANOGENESIS HOLDINGS INC.
Net worth: 424 932 $ as of 31/03/2024
Profile
Michele I.
Korfin's current job(s) include serving as an Independent Director at Organogenesis Holdings, Inc. since 2022 and as Secretary & Trustee at BioNJ, Inc. since 2020.
Ms. Korfin's former job(s) include being the Head-Oncology Sales Force at Celgene Corp.
from 2004 to 2016, Chief Operating Officer at Tyme Technologies, Inc. from 2019 to 2020, Vice President-Market Access at Kite Pharma, Inc. from 2016 to 2018, and Chief Operating & Commercial Officer at Gamida Cell Ltd.
from 2020 to 2024.
Ms. Korfin's education history includes an undergraduate degree from Rutgers State University of New Jersey and an MBA from Harvard Business School.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 21/02/2024 | 140,670 ( 0.11% ) | 399 503 $ | 31/03/2024 | |
GAMIDA CELL LTD.
0.53% | 15/03/2024 | 706,380 ( 0.53% ) | 25 430 $ | 31/03/2024 |
Michele Korfin active positions
| Companies | Position | Start |
|---|---|---|
| ORGANOGENESIS HOLDINGS INC. | Director/Board Member | 03/05/2022 |
BioNJ, Inc.
 BioNJ, Inc. Miscellaneous Commercial ServicesCommercial Services BioNJ, Inc. is based in Trenton, NJ. BioNJ, Inc. is a life sciences trade association with nearly 400 member companies. The company supports the discovery, development, and commercialization of therapies and cures that save and improve lives. BioNJ drives capital formation, fosters entrepreneurship, advocates for medical innovation, provides access to talent and education, and offers critical commercial resources. The company also serves as a clearinghouse for funding information and opportunities. The company was founded in 1994 by James J. Marino, Jayne C. Gershkowitz, Abraham Abuchowski. The CEO is Debbie Hart. | Director/Board Member | - |
Former positions of Michele Korfin
| Companies | Position | End |
|---|---|---|
| GAMIDA CELL LTD. | Chief Operating Officer | 01/04/2024 |
| TYME TECHNOLOGIES, INC. | Chief Operating Officer | 01/01/2020 |
| KITE PHARMA INC | Corporate Officer/Principal | 01/07/2018 |
| CELGENE | Corporate Officer/Principal | 01/03/2016 |
Training of Michele Korfin
| Rutgers State University of New Jersey | Undergraduate Degree |
| Harvard Business School | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| GAMIDA CELL LTD. | Health Technology |
| ORGANOGENESIS HOLDINGS INC. | Health Technology |
| Private companies | 4 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Tyme Technologies, Inc.
 Tyme Technologies, Inc. Pharmaceuticals: MajorHealth Technology Tyme Technologies, Inc. operates as a biotechnology company, which engages in the development and commercialization of cancer therapies. It offers a clinical program named SM-88 which is a novel, oral, and monotherapy investigational agent that aims to disrupt the cancer cell's protein synthesis. The company was founded by Steve Hoffman and Michael Demurjian on November 22, 2011 and is headquartered in Bedminster, NJ. | Health Technology |
BioNJ, Inc.
BioNJ, Inc. Miscellaneous Commercial ServicesCommercial Services BioNJ, Inc. is based in Trenton, NJ. BioNJ, Inc. is a life sciences trade association with nearly 400 member companies. The company supports the discovery, development, and commercialization of therapies and cures that save and improve lives. BioNJ drives capital formation, fosters entrepreneurship, advocates for medical innovation, provides access to talent and education, and offers critical commercial resources. The company also serves as a clearinghouse for funding information and opportunities. The company was founded in 1994 by James J. Marino, Jayne C. Gershkowitz, Abraham Abuchowski. The CEO is Debbie Hart. | Commercial Services |
Kite Pharma, Inc.
 Kite Pharma, Inc. BiotechnologyHealth Technology Kite Pharma, Inc. engages in the the development and commercialization of cancer immunotherapy products. Its products include chimeric antigen receptor (CAR) and T cell receptor (TCR), which address both hematological and solid cancers. The company was founded by Arie S. Belldegrun, James S. Economou, and Joshua A. Kazam on 2009 and is headquartered in Santa Monica, CA. | Health Technology |
- Stock Market
- Insiders
- Michele Korfin